Endo CCH asset remain underappreciated, says Canaccord

Canaccord analyst Dewey Steadman met with Endo management and came away with the belief the Street continues to undervalue the CCH asset. He believes CCH, along with strong core business performance and relatively manageable cash outflows, make for a compelling story with the shares attractively priced. Steadman reiterated his Buy rating and $20 price target on Endo shares.
https://thefly.com/landingPageNews.php?id=2848101